Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Diagnostic radiopharmaceuticals | 1 |
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
FAP(Fibroblast activation protein alpha) | 1 |
CTNNB1(Catenin beta 1) | 1 |
Mechanism EGFR antagonists [+1] |
Active Org.- |
Originator Org.- |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CTNNB1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FAP modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date14 Aug 2024 |
Sponsor / Collaborator |
Start Date03 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GB-1874 ( CTNNB1 ) | Colorectal Cancer More | Preclinical |
18F-RO-7016970 ( FAP ) | Pulmonary Fibrosis More | Preclinical |
Triptolide ( EGFR x HSP70 heat-shock proteins ) | Breast Cancer More | Discontinued |
Isocitrate dehydrogenase inhibitors (Daiichi Sankyo) ( IDH1 x IDH2 ) | Neoplasms More | Pending |
PRN-371 ( JAK3 ) | T-Cell Lymphoma More | Pending |